ATE405654T1 - Polypeptid mit verbesserter cytosin-deaminase- aktivität - Google Patents

Polypeptid mit verbesserter cytosin-deaminase- aktivität

Info

Publication number
ATE405654T1
ATE405654T1 AT04744156T AT04744156T ATE405654T1 AT E405654 T1 ATE405654 T1 AT E405654T1 AT 04744156 T AT04744156 T AT 04744156T AT 04744156 T AT04744156 T AT 04744156T AT E405654 T1 ATE405654 T1 AT E405654T1
Authority
AT
Austria
Prior art keywords
polypeptide
activity
deeaminase
cytosine
improved
Prior art date
Application number
AT04744156T
Other languages
English (en)
Inventor
Philippe Erbs
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE405654T1 publication Critical patent/ATE405654T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04744156T 2003-07-21 2004-06-29 Polypeptid mit verbesserter cytosin-deaminase- aktivität ATE405654T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03360087 2003-07-21
US50827403P 2003-10-06 2003-10-06

Publications (1)

Publication Number Publication Date
ATE405654T1 true ATE405654T1 (de) 2008-09-15

Family

ID=39719832

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04744156T ATE405654T1 (de) 2003-07-21 2004-06-29 Polypeptid mit verbesserter cytosin-deaminase- aktivität

Country Status (16)

Country Link
US (3) US7790445B2 (de)
EP (2) EP1897938B9 (de)
JP (1) JP4672659B2 (de)
KR (1) KR101062140B1 (de)
CN (1) CN1826410B (de)
AT (1) ATE405654T1 (de)
AU (1) AU2004257935B2 (de)
CA (1) CA2532783C (de)
CY (1) CY1110397T1 (de)
DE (1) DE602004015995D1 (de)
DK (1) DK1649023T3 (de)
ES (1) ES2311831T3 (de)
IL (1) IL173158A (de)
PL (1) PL1649023T3 (de)
PT (1) PT1649023E (de)
WO (1) WO2005007857A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2489486C2 (ru) 2006-06-20 2013-08-10 Трансжене С.А. Процесс получения поксвирусов и композиции поксвирусов
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
BRPI0811787B1 (pt) 2007-07-03 2018-10-09 Transgene Sa usos de uma célula imortalizada e processo para imortalizar uma célula aviária
DK2346995T3 (en) * 2008-09-26 2019-02-11 Tocagen Inc GENETERIVE VECTORS AND CYTOSINDEAMINASES
SG176554A1 (en) 2009-05-12 2012-01-30 Transgene Sa Method for orthopoxvirus production and purification
AU2010275764A1 (en) 2009-07-21 2012-03-15 Transgene Sa Enzymatic composition for the digestion of chicken embryos
EP2527432A1 (de) * 2011-05-23 2012-11-28 Novozymes A/S Bidirektionaler Cytosin-Deaminase-codierender Selektionsmarker
WO2013004658A1 (en) 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
KR102457060B1 (ko) 2014-04-10 2022-10-19 트랜스진 폭스바이러스 종양용해 벡터
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
US10517943B2 (en) 2014-12-01 2019-12-31 Transgene S.A. Stable liquid vaccinia virus formulations
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
US20190038676A1 (en) * 2016-02-05 2019-02-07 Slbigen Inc. Mesenchymal stem cell expressing trail and cd, and use thereof
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
AU2017272721B2 (en) * 2016-05-30 2023-03-30 Astellas Pharma Inc. Novel genetically engineered vaccinia viruses
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
CA3093093A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
PH12021550661A1 (en) 2018-09-26 2022-03-21 Astellas Pharma Inc Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
KR20250052416A (ko) 2022-08-18 2025-04-18 트랜스진 키메라 폭스바이러스

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
FR2583429B1 (fr) * 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
CA2018273C (en) 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
DK0689447T3 (da) 1993-02-16 1999-10-18 Onyx Pharma Inc Cytopatiske vira til behandling af og profylakse for neoplasia
AU6953394A (en) * 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2762615B1 (fr) 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
FR2777570A1 (fr) * 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
US6552005B1 (en) * 1998-09-29 2003-04-22 Uab Research Foundation Molecular chemotherapy enhancement of radiotherapy
US20030121068A1 (en) 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
US7141404B2 (en) 2002-12-27 2006-11-28 Onyx Pharmaceuticals, Inc. Candida kefyr cytosine deaminase

Also Published As

Publication number Publication date
HK1112024A1 (en) 2008-08-22
CA2532783C (en) 2013-09-17
CN1826410A (zh) 2006-08-30
US8226954B2 (en) 2012-07-24
JP4672659B2 (ja) 2011-04-20
EP1649023A1 (de) 2006-04-26
PT1649023E (pt) 2008-11-20
EP1897938B1 (de) 2010-10-06
CY1110397T1 (el) 2015-04-29
PL1649023T3 (pl) 2009-01-30
IL173158A0 (en) 2006-06-11
US7790445B2 (en) 2010-09-07
KR101062140B1 (ko) 2011-09-05
US8257692B2 (en) 2012-09-04
DE602004015995D1 (de) 2008-10-02
EP1649023B1 (de) 2008-08-20
WO2005007857A1 (en) 2005-01-27
IL173158A (en) 2009-12-24
KR20060040697A (ko) 2006-05-10
AU2004257935A1 (en) 2005-01-27
DK1649023T3 (da) 2008-10-06
JP2006527994A (ja) 2006-12-14
EP1897938B9 (de) 2011-08-31
US20100330051A1 (en) 2010-12-30
AU2004257935B2 (en) 2009-11-19
US20070264235A1 (en) 2007-11-15
EP1897938A1 (de) 2008-03-12
US20100330031A1 (en) 2010-12-30
ES2311831T3 (es) 2009-02-16
HK1084150A1 (en) 2006-07-21
CA2532783A1 (en) 2005-01-27
CN1826410B (zh) 2011-10-26

Similar Documents

Publication Publication Date Title
CY1110397T1 (el) Πολυπεπτιδιο που εχει βελτιωμενη δραστικοτητα αποαμινασης κυτοσινης
DE502005006284D1 (de) Keratin-bindende polypeptide
DK1651166T3 (da) Polypeptid til induktion af et beskyttende immunrespons mod staphylococcus aureus
DK1423419T3 (da) Hybrid- og tandemekspression af Neisseria-proteiner
DK1454138T3 (da) Immunocytokiner med moduleret selektivitet
EP1496123A4 (de) Acetolactatsynthase codierende gene
EA201200398A1 (ru) Полипептиды с оксидоредуктазной активностью и их применение
EP1801206A4 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
BRPI0517493A (pt) polinucleotìdeo isolado, promotor vetor de expressão, célula hospedeira e uso de um polinucleotìdeo
EA201000002A1 (ru) Полипептид апф2
NO20063026L (no) Antistoffer
NZ774126A (en) Spd-1 variant - fc fusion proteins
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
EA200801464A1 (ru) Способ и система для компенсации вызванного внутренними причинами смещения ткани
BRPI0307702B8 (pt) formulações de solução contendo anticorpo
EP4374913A3 (de) Neuartiger humaner serumalbuminmutant
DE60237791D1 (de) Zytokinproteinfamilie
DE50213015D1 (de) Lipase-varianten
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung
NO20082864L (no) Nytt polypeptid med esteraseaktivitet og rekombinant esterase samt anvendelse derav
EP1467207A4 (de) Screening-verfahren
SE0101519D0 (sv) Nucleic ACID
DE602005025989D1 (de) Von 2',3'-didesoxynucleosiden und 2',3'-didehydro-2',3'-didesoxynucleosiden
ATE387494T1 (de) Hitzelabile desoxyribonuklease i-varianten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1649023

Country of ref document: EP